Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127826 | 1.00 | HSPD1 (0.37) | HSPD1BLMHSPE1GPR84CA2 | |
| SCHEMBL10423885 | 0.89 | HSPD1 (0.31) | HSPD1BLMHSPE1CA2 | |
| SCHEMBL127781 | 0.81 | TP53 (0.32) | CA2PSMD14PLA2G1BMMP2ATG4B | |
| SCHEMBL8660433 | 0.81 | CPT2 (0.33) | HSPD1BLMHSPE1 | |
| SCHEMBL1177056 | 0.79 | PLA2G2C (0.41) | PLA2G1B | |
| SCHEMBL7776655 | 0.76 | HSPD1 (0.36) | HSPD1BLMHSPE1GPR84CA2 | |
| SCHEMBL126197 | 0.76 | HSPD1 (0.36) | HSPD1BLMHSPE1GPR84CA2 | |
| SCHEMBL3829472 | 0.74 | FABP3 (0.39) | BLMMMP2FFAR1FFAR4 | |
| SCHEMBL5997470 | 0.72 | TDP1 (0.40) | HSPD1BLMHSPE1GPR84FFAR1 | |
| SCHEMBL9437219 | 0.72 | TDP1 (0.40) | HSPD1BLMHSPE1GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-10-26 | — | — | US | claimed |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-24 | — | — | US | claimed |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-17 | — | — | US | claimed |
| WO-2024096874-A1 | ORGANIC BASE, ORGANIC BASE FORMULATIONS, AND ASSOCIATED METHODS FOR PREPARING THE SAME | BERREYESA MAX (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150610-A1 | Cationic-Stabilized Dispersions, Hybridized Cationic-Stabilized Dispersions, In-Mold Coated Articles Prepared Utilizing Such Stabilized Dispersions, and Methods for Manufacturing Same | RED SPOT PAINT & VARNISH CO., INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240110132-A1 | POTENTIAL OF HYDROGEN (pH) STABILIZED CLEANING FORMULATIONS | ENVIROX, L.L.C. | 2024-04-04 | — | — | US | disclosed |
| WO-2024058857-A1 | POTENTIAL OF HYDROGEN (PH) STABILIZED CLEANING FORMULATIONS | EnvirOx, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240081344-A1 | PLANT NUTRIENT FORMULATION AND METHOD FOR PREPARING THE SAME | BERREYESA MAX (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3310893-B2 | IMPROVEMENTS IN OR RELATING TO ENCAPSULATED PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20240043775-A1 | STABILIZATION OF HYDROGEN PEROXIDE CONTAINING FORMULATIONS WITH TWO-COMPONENT SYNERGISTIC STABILIZERS | ENVIROX, L.L.C. | 2024-02-08 | — | — | US | disclosed |
| WO-2024025764-A1 | STABILIZATION OF HYDROGEN PEROXIDE CONTAINING FORMULATIONS WITH TWO-COMPONENT SYNERGISTIC STABILIZERS | EnvirOx, LLC (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2013003601-A1 | METHOD FOR TREATING PHYTOPHOTODERMATITIS | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013003560-A1 | METHOD FOR TREATING ECZEMA | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2013-01-03 | — | — | WO | disclosed |
| US-20120202878-A1 | METHOD FOR TREATING PSORIASIS | WILLIAM M. YARBROUGH FOUNDATION, THE | 2012-08-09 | — | — | US | disclosed |
| US-20120190742-A1 | METHOD FOR TREATING ECZEMA | WILLIAM M. YARBROUGH FOUNDATION, THE | 2012-07-26 | — | — | US | disclosed |
| US-20120184621-A1 | METHOD FOR TREATING PHYTOPHOTODERMATITIS | WILLIAM M. YARBROUGH FOUNDATION, THE | 2012-07-19 | — | — | US | disclosed |
| EP-0941059-B1 | FOAMABLE SKIN PREPARATIONS | JOHNSON & SON INC S C (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-0941059-A1 | FOAMABLE SKIN PREPARATIONS | S.C. JOHNSON & SON, INC. (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998020854-A1 | FOAMABLE SKIN PREPARATIONS | S.C. JOHNSON & SON, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-4699728-A | DISCOLORATION INHIBITION | ECOLAB, INC. (US) | 1987-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043775-A1 | STABILIZATION OF HYDROGEN PEROXIDE CONTAINING FORMULATIONS WITH TWO-COMPONENT SYNERGISTIC STABILIZERS | LPO, GPX4, GPX1 | HSPD1 281/4885BLM 1508/4885HSPE1 262/4885 |
| US-20120184621-A1 | METHOD FOR TREATING PHYTOPHOTODERMATITIS | STOM, TST, ABCB4 | HSPD1 560/4885BLM 2666/4885HSPE1 473/4885 |
| US-20120190742-A1 | METHOD FOR TREATING ECZEMA | CCL11, TYR, ITCH | HSPD1 3483/4885BLM 4231/4885HSPE1 2492/4885 |
| US-20120202878-A1 | METHOD FOR TREATING PSORIASIS | SPAST, TMSB10, IL33 | HSPD1 1240/4885BLM 4684/4885HSPE1 1258/4885 |
| US-20240081344-A1 | PLANT NUTRIENT FORMULATION AND METHOD FOR PREPARING THE SAME | SHBG, VDR, CYP24A1 | HSPD1 3694/4885BLM 3289/4885HSPE1 4083/4885 |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | MIF, TNF, MMP12 | HSPD1 3615/4885BLM 3899/4885HSPE1 3566/4885 |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | CFTR, TST, ICMT | HSPD1 1133/4885BLM 1503/4885HSPE1 1010/4885 |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | BPHL, KLK3, ACP3 | HSPD1 1683/4885BLM 2339/4885HSPE1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.